Compare Amphastar Pharmaceuticals Inc (AMPH) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Schwab US Large Cap Growth ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Schwab US Large Cap Growth ETF trades at $35.69. The key difference: Schwab US Large Cap Growth ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | SCHG | |
|---|---|---|
Market Cap | $863.95M | — |
Sector | Health | Sector/Thematic |
52-Week High | $30.81 | $35.83 |
52-Week Low | $16.87 | $28.10 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
SCHG trades at $35.78, up 1.02% today, with a bullish technical signal from moving averages and strong trend strength (ADX). The ETF's low 0.04% expense ratio and concentrated exposure to AI-driven tech giants like Nvidia and Microsoft support growth potential, though key valuation metrics are unavailable. Recent news highlights institutional position adjustments and AI capital expenditure tailwinds.
Outlook remains positive due to AI growth catalysts and cost efficiency, but risks include high concentration in top holdings and sensitivity to tech sector volatility. Analyst sentiment is mixed, with some citing premium valuations as a concern for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
